Evidence map›Paper›PMID 42363259›Full record

ArticleStem cell research & therapy2026

Dexamethasone reduces osteogenic potential through suppressing retinoic acid signaling via NF-κB/CYP26B1 axis in mesenchymal stem cells.

Ai-Hua Ye, Yu-Mei Wang, Xin-Yue Wan, Jia Liu, Ni Tang, Wen-Ting Liu, Jie Cai, Dong-Mei He, Bai-Cheng He, Wen-Ge He and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ai-Hua Ye *Key Laboratory of Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing, 400016, People's Republic of China.
Yu-Mei Wang *Department of Bone and Soft Tissue Tumors, School of Medicine, Chongqing University Cancer Hospital, Chongqing University, No. 181 Hanyu Road, Shapingba District, Chongqing, 400030, China.
Xin-Yue WanDepartment of Bone and Soft Tissue Tumors, School of Medicine, Chongqing University Cancer Hospital, Chongqing University, No. 181 Hanyu Road, Shapingba District, Chongqing, 400030, China.
Jia LiuDepartment of Bone and Soft Tissue Tumors, School of Medicine, Chongqing University Cancer Hospital, Chongqing University, No. 181 Hanyu Road, Shapingba District, Chongqing, 400030, China.
Ni TangDepartment of Bone and Soft Tissue Tumors, School of Medicine, Chongqing University Cancer Hospital, Chongqing University, No. 181 Hanyu Road, Shapingba District, Chongqing, 400030, China.
Wen-Ting LiuKey Laboratory of Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing, 400016, People's Republic of China.
Jie CaiKey Laboratory of Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing, 400016, People's Republic of China.
Dong-Mei HeKey Laboratory of Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing, 400016, People's Republic of China.
Bai-Cheng HeKey Laboratory of Biochemistry and Molecular Pharmacology of Chongqing, Chongqing Medical University, Chongqing, 400016, People's Republic of China. bche@cqmu.edu.cn.
Wen-Ge HeDepartment of Bone and Soft Tissue Tumors, School of Medicine, Chongqing University Cancer Hospital, Chongqing University, No. 181 Hanyu Road, Shapingba District, Chongqing, 400030, China. cqmu_hwg1995@163.com.
Liang ChenDepartment of Bone and Soft Tissue Tumors, School of Medicine, Chongqing University Cancer Hospital, Chongqing University, No. 181 Hanyu Road, Shapingba District, Chongqing, 400030, China. Chen.liang.1979@cqu.edu.cn.

Funding

Chongqing Innovative Medical Device Application Demonstration Project CQEIC2024MDAD-010Chongqing Municipal Science and Technology Bureau CSTB2024NSCQ-MSX0411Science and Technology Research Project of Chongqing Municipal Education Commission KJQN202300125
6 · The paper itself

Abstract

objectiveGlucocorticoid-induced osteoporosis (GIOP) is the most common secondary osteoporosis, which characterized by the decreased bone strength and increased fracture risk. But the pathogenic causes of GIOP remains not completely yet. In this study, we investigated the effect of Cyp26b1, a key enzyme for all-trans retinoic acid (ATRA) degradation, on the osteogenic inhibitory effect of dexamethasone (DEX) in mesenchymal stem cells (MSCs) and revealed the possible mechanism through which DEX regulates the expression of Cyp26b1.

methodsMSCs were induced with osteogenic induction medium in vitro to establish the osteogenic model, and high concentration (10

resultsDEX (10

conclusionThe osteogenic inhibitory effect of high concentration of DEX may be resulted from the disturbance of retinoic acid signaling. The expression of Cyp26b1 can be up-regulated by either low or high concentration of DEX, but its degradation can only be inhibited by high concentration of DEX. The effect of DEX on Cyp26b1 expression was partially mediated by activating NF-κB signaling in MSCs.

Indexed as

DexamethasoneMesenchymal Stem CellsNF-kappa BOsteogenesisRetinoic Acid 4-HydroxylaseTretinoinAnimalsCell DifferentiationCells, CulturedMaleOsteoporosisRatsRats, Sprague-DawleySignal TransductionCyp26b1 protein, ratDexamethasoneNF-kappa BRetinoic Acid 4-HydroxylaseTretinoinCytochrome P450 family 26 subfamily B member 1Glucocorticoid-induced osteoporosisMesenchymal stem cellsNuclear factor-kappa BRetinoic acid signaling

Identifiers

PMID42363259
PMCPMC13579854

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.